Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Boehringer bags PVT’s viral vector platform for cancer vaccine R&D

Boehringer bags PVT’s viral vector platform for cancer vaccine R&D

July 7, 2026Posted inBiotechnology

Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologies’ viral vector platform for developing next-generation cancer vaccines.

Post navigation

Previous Post
Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical
Next Post
Endevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1s

Recent Posts

  • Sawdust-Based Material Effectively Cleans Dye and Food Processing Wastewater
  • Kidney Disease Rates Stable, Increasing Among Diabetes and Heart Patients in US
  • ISSCR 2026 Launches in Montréal with Global Stem Cell Science Summit
  • Reinforcement Learning Advances Quantum Error Correction Control
  • Linoleic Acid Promotes Osteoarthritis via Ferroptosis in Male Rat Cartilage

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top